DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0177276 A1 L0 Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 2016O177276A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0177276 A1 L0 et al. (43) Pub. Date: Jun. 23, 2016 (54) SIRP-ALPHA IMMUNOGLOBULINFUSION C07K 6/40 (2006.01) PROTEINS C07K 16/32 (2006.01) C07K 6/28 (2006.01) (71) Applicant: MERCK PATENT GMBH, Darmstadt C07K 6/30 (2006.01) (DE) (52) U.S. Cl. CPC .............. CI2N 9/16 (2013.01); C07K 16/2887 (72) Inventors: Kin-Ming Lo, Lexington, MA (US); (2013.01); C07K 16/30 (2013.01); C07K Nora Zizlsperger, Newton, MA (US); I6/2863 (2013.01); C07K 16/40 (2013.01); Aroop Sircar, Billerica, MA (US) C07K 16/32 (2013.01); C07K 16/18 (2013.01); 21) Appl. No.: 14/827,003 C07K 16/2827 (2013.01);s C07K 16/2803 (21) Appl. No 9 (2013.01); C12Y-301/03048 (2013.01); C07K (22) Filed: Aug. 14, 2015 2317/622 (2013.01); C07K 2319/74 (2013.01); A6 IK 2039/505 (2013.01) Related U.S. Application Data (60) Provisional application No. 62/038,196, filed on Aug. (57) ABSTRACT 15, 2014. Publication Classification The invention discloses immunoglobulin fusion proteins designed to bind both CD47 and a tumor cell antigen. The (51) Int. Cl. immunoglobulin fusion proteins include a SIRPC. moiety that CI2N 9/16 (2006.01) binds CD47 and an antigen binding site for a tumor cell C07K 6/8 (2006.01) antigen. Patent Application Publication Jun. 23, 2016 Sheet 1 of 36 US 2016/0177276 A1 2 EVE CL Patent Application Publication Jun. 23, 2016 Sheet 2 of 36 US 2016/0177276 A1 Patent Application Publication Jun. 23, 2016 Sheet 3 of 36 US 2016/0177276 A1 FG. K Patent Application Publication Jun. 23, 2016 Sheet 4 of 36 US 2016/0177276 A1 FG. Patent Application Publication Jun. 23, 2016 Sheet 5 of 36 US 2016/0177276 A1 2 3 4. 5 8 7 8 DAY'S OS.REAVENT FG. 2A 4 2 7 8 DAYS POS-TREAVEN F.G. 2B Patent Application Publication Jun. 23, 2016 Sheet 6 of 36 US 2016/0177276 A1 KDa N 183 98 62 49 38 FG. 3A 28 4. 8 3 900 80 70) 60 500 40 30 ... 1200 . O 100 90 80 70 60 50 40 30 20 5.465 5.966 O ( ; 2 3 4 5 & 7 8 & 10 1 2 3 4 5 TIME (min) G. 33 Patent Application Publication Jun. 23, 2016 Sheet 7 of 36 US 2016/0177276 A1 20 --Or Anti-CD20-hugG1-huSRPaV2 000 rty's F-SiRPW2 a: sis SRPW2-r f o:mo" : obo Anti-C20 pe 80 -- Anti-CD47 / oak 6 O 8 . RED BLOOD CELLS (CD235+) to E. LEUKOCYTES (CD45*) 5 t h Atop top. Antonio SRPCV2 SRPCV2. FC SRPCV2 FG. 4B Patent Application Publication Jun. 23, 2016 Sheet 8 of 36 US 2016/0177276 A1 400 so -o- Anti-CD20-hugG1-huSIRPaV2 : • 'A' FC-huSRPV2 A. g 300 oar- huSIRPav2-Fo A. i 250 -a-. Anti-CD47 f S 200 ti- s a 150 f 100 5 :e : 0. G. 4C 90 8) --Or Anti-CD20-huigG-huSRPaV2 : sexy. FC-SRPoV2 1. 70 -- Anti-CD20 1 i?S 60a - - Anti-CD47 s 50 is 40 2. is 30 e s' & 88 w st , 000 Patent Application Publication Jun. 23, 2016 Sheet 9 of 36 US 2016/0177276 A1 EDAs SURVIVA. DAYS wy w CONTRO. At mem. Anti-CD20 3S or Anti-CD47 143 {{ YYYYYYYYYYYYYYYY PPPPPPPPPPPPPPPPAwww.wa. A v. A was w8A wa &w A w w 8A wir aw Ove Anti-C2ianti-CD4F NO --- e k ?s 75 - 8 5 50 - y r - 25 1 a v g 20 40 80 8 OO 20 4 6 8 AYS POS iOR NOCAON F.G. 5A RA 8 mmm's iANSRWVA DAYS a - p SOTYPE CONTRO 3 80 on RXAN 8 w -" cooroo Anti-C47 37 6 (... as Os Anti-CD2O:Anti-C47 55 Patent Application Publication Jun. 23, 2016 Sheet 10 of 36 US 2016/0177276 A1 Ka 88 F.G. 6A Patent Application Publication Jun. 23, 2016 Sheet 11 of 36 US 2016/0177276 A1 anti-EGFR-huigG1-SRPow 5.561 6,025 (. 1 2 3 4 5 & 7 & 8 to 1 2 3 4 5 TIME (min) 380 6.8 i. 81 anti-EGFR-hulgG1-(G4S): SIRPoV2 2400 2200 2}} 1800 160040 20 000 8 6 4- 5,473 5.987 ; ; ; ; ; ; ; ; , , , , , , TIME (min) F.G. 6B Patent Application Publication Jun. 23, 2016 Sheet 12 of 36 US 2016/0177276 A1 (ii) anti-EGFR-hulgG1-(G4S4-SiRPoV2 :0 5.451 5985 2 3 4. " " " " . TIME (min) 2800 8.75- anti-EGFR-hulgG1-(G4S)5-SIRPoV2 is TIVE (min) FIG. 6B (CONT) Patent Application Publication Jun. 23, 2016 Sheet 13 of 36 US 2016/0177276 A1 1000 -k- Anti-EGFR-hugg1-h;SRPaw -- Anti-EGFR-hugg1-G4S)3-huSiRPaV2 & Anti-EGFR-hugG-G4S4-huSRPaV2 800 --- Anti-EGFR-hugg1-G4S5-huSiRPaV2 ...y. FC-SRPOW2 Mir SRPCW2-Fi 600 - - Anti-CED47 ... Atti-EGFR a a.s. 40 es 2 -: w 200 ->k x O.01 . 0.1 O OO 300 ni FG, 7A 90 . 80 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - RE BOOD CELS (CD235+) 70. E. EUKOCYTES (CD45+) 60 . g 50 - is 40-rrier to r as 30 - . : . :::::::::. 3. : . 20.... : ... ... : ... :... ... :. O . : . ::::::::. : . : . O+ hu Atop to of SRPW2 SRPx2-C hSRPOW G. 73 Patent Application Publication Jun. 23, 2016 Sheet 14 of 36 US 2016/0177276 A1 --C - Anti-EGFR-huigG-huSRPaV2 120 vyy FC-SRPCV2 wiro Sirf2-FC g O m:m Angpt mm. Anti-EGFR i. 3 80 it 60 s e 40 C O,000 O, OO 0000 Patent Application Publication Jun. 23, 2016 Sheet 15 of 36 US 2016/0177276 A1 2000000 - -o- Anti-EGFR-huigG-(G4S4-huSRPaV2 orro hSir POV2-r 1800000 ...A.. Fc-husiRPv2 ---O- - 800000 - obo Anti-EGFR o r 4000 200000 000000 800000 600000 400000 200000 O R 0.000 0.00 3.0 O. 10 00 Patent Application Publication Jun. 23, 2016 Sheet 16 of 36 US 2016/0177276 A1 00). -- Fe-SiRPo (20 ag) r^ - FC-SRPo (200 g) we anti-EGFR-Fe-SRPo (20 kg) ...O.. anti-EGFR-FC-SRPoi. (200 g) 0. t 50 100 50 200 250 TIME (h) G. 9A EDAN SRWWA DAYS O ope - SOTYPE CONTRO 28 oboe C225 3. 80 wim SRPa-FC 3. -- C225+ SRPa-Fo 4. 60 w C a C225iSR-a-F 40 40 20 to 2 3 4 so 70 DAYS OS.REAVEN START G. 9B Patent Application Publication Jun. 23, 2016 Sheet 17 of 36 US 2016/0177276 A1 FG. OA 2 3 4 5 6 7 & 8 to 12 13 14 15 TIME (min) FG. OB Patent Application Publication Jun. 23, 2016 Sheet 18 of 36 US 2016/0177276 A1 2000. --O- Anti-HER2-huigG4-h;SRPav2 180 - sexx as F-SRPo V2 .. othro h;SRPCV2-F2 e: 600 -- Anti-CD47 oboe Anti-ER2 4. O -: 4. 80 - / 2 800 - 30 200 - O ::::::: 3. O, . COO f FG. A 80. RED BLOOD CELLS (CD235t) 7 - . s' EUKOCYTES (CD45+) 8 O F. Anti-CD47 "Antier. Anti-ER SRC.V2 SRPCV2-C SR-V2 G. 13 Patent Application Publication Jun. 23, 2016 Sheet 19 of 36 US 2016/0177276 A1 400 - O - Anti-HER2-hulgG-huSRPaV2 ...yo. FC-hSRPOW2 20 on Anti-CD47 --- obo Anti-ER2 exo-boo" 800 800 400 200 F.G. 11C Patent Application Publication Jun. 23, 2016 Sheet 20 of 36 US 2016/0177276 A1 2200 2 200 30 800 47 8. 500 4. 30 25. 3. 800 700 8. 500 4. 3. 2 552 6,044 84.79,524 00 O 2 3 4 5 & 7 8 to 1 2 3 4 15 TIME (min) FG. 2B Patent Application Publication Jun. 23, 2016 Sheet 21 of 36 US 2016/0177276 A1 " -o- Anti-PDL1-hulgG1-muSIRPa. * -e-A. Anti-PDL4FC-muSIRPe. 10- -- huigG1 control i 0. ----------------------------------------- Gioboo oooo- O. 4 100 0000 Patent Application Publication Jun. 23, 2016 Sheet 22 of 36 US 2016/0177276 A1 Ka 88 98 62 49 38 FG. AA 28 280 260 2400 22 200 8 3. S. 4 2 {{0 800 60 400 2 5,486 5.984 ( ----------------------------------------------------------------------------------------------------------------------------------------------------; 2 3 4 5 & 7 & 8 to 12 3 4 5 TIME (min) FG. 4B Patent Application Publication Jun. 23, 2016 Sheet 23 of 36 US 2016/0177276 A1 900 wk- Anti-EGFR-huigG1-huSERPaV1 80 -x- Anti-EGFR-higG1-huSRPawt (N110C) OO c. Anti-EGFR-huggi-(G4S)4-huSRPaV2 A. Fo-SERPOV2 6 orro SRPoV2-Fe: -Do Anti-CD47 500 -- Anti-EGFR 4. 30 200 {{ O 8:: aaaa...: s 8 : 0.00 O.) O. O 00 000 Patent Application Publication Jun. 23, 2016 Sheet 24 of 36 US 2016/0177276 A1 FG. 6A 5,583 5.988 Y " --------------------------------------------------------------------------------------------------------------------------------------------------------" " " " " " " " " " " "," "is TIME (min) F.G. 18B Patent Application Publication Jun. 23, 2016 Sheet 25 of 36 US 2016/0177276 A1 --> huSRPoV2-FChuigG1}-anti-EGFR(Fab) ..o. Anti-EGFR-huggi-G4S4-huSRPaV2 war. SRPCV2-FC 700 A. Fo-huSRPoV2 600 - - - Anti-CR47 8 r"a oo::co. Anti-EGFr 300 g ...A is 400 - A A' g ... is 300 O ----------- (Bexel : -. 0.00 . O 100C f F.G. 17A w{v: huSRPoV2-FChuigG1}-anti-EGFR(Fab) 20000 - O - Anti-EGFR-huggi-G4S}4-huSRPaV2 3000 mew SRPCV2-C ---O- 600000 oyye FC-SRFCV2 O K1 wo-born Anti-EGFR 4000 2000 00000 8000 60 -4- 400000 - ? / 2000 geo OOOO . 0. 0. 00 f F.G. 17B Patent Application Publication Jun. 23, 2016 Sheet 26 of 36 US 2016/0177276 A1 EAN SRWWA DAYS wo wo orps SOTYPE CONTRO. 29.5 minor Ani-EGFR 35.5 m-go Ai-EGFr + SRParc 42 x X x Aiii-EGFRSRPa 43.
Recommended publications
  • Strategies to Enhance Monoclonal Antibody Uptake and Distribution in Solid Tumors

    Strategies to Enhance Monoclonal Antibody Uptake and Distribution in Solid Tumors

    Cancer Biol Med 2021. doi: 10.20892/j.issn.2095-3941.2020.0704 REVIEW Strategies to enhance monoclonal antibody uptake and distribution in solid tumors Brandon M. Bordeau, Joseph P. Balthasar Department of Pharmaceutical Science, University at Buffalo, Buffalo, NY 14214, USA ABSTRACT Despite the significant resources dedicated to the development of monoclonal antibody (mAb) therapies for solid tumors, the clinical success, thus far, has been modest. Limited efficacy of mAb in solid tumors likely relates to unique aspects of tumor physiology. Solid tumors have an aberrant vasculature and a dense extracellular matrix that slow both the convective and diffusive transport of mAbs into and within tumors. For mAbs that are directed against cellular antigens, high antigen expression and rapid antigen turnover can result in perivascular cells binding to and eliminating a significant amount of extravasated mAb, limiting mAb distribution to portions of the tumor that are distant from functional vessels. Many preclinical investigations have reported strategies to improve mAb uptake and distribution; however, to our knowledge, none have translated into the clinic. Here, we provide an overview of several barriers in solid tumors that limit mAb uptake and distribution and discuss approaches that have been utilized to overcome these barriers in preclinical studies. KEYWORDS Solid tumors; antibody uptake and distribution; monoclonal antibody; antibody–drug conjugate Introduction Currently, monoclonal antibodies (mAbs) are heralded as the “magic bullets” that Ehrlich envisioned, and in many cases, the In 1900, Paul Ehrlich developed the receptor theory, which moniker is well deserved. Antibodies can bind most substances was built on the foundational hypothesis that toxins, nutri- with high affinity and high selectivity and are used for the treat- ents, and drugs exert their observed effect through binding to ment of many diseases.
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology

    Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology

    Figure 1. This is a pilot view to explore the potential of EpiGraphDB to inform us about proteins that are linked to the pathophysiology of cancer and cardiovascular disease (CVD). For each cancer type (pink diamonds), we searched for cancer related proteins (light blue circles) that interact with other proteins identified as protein quantitative trait loci (pQTLs) for CVD (red diamonds for pathologies, orange triangles for risk factors). These pQTLs can be acting in cis (solid lines) or trans-acting (dotted lines). Proteins can interact either directly, a protein-protein interaction (dotted blue edges), or through the participation in the same pathway (red parallel lines). Shared pathways are represented with blue hexagons. We also queried which of these proteins are targeted by existing drugs. We found that the cancer drug cetuximab (yellow circle) inhibits EGFR. Other potential drugs are depicted in light brown hexagonal meta-nodes that are detailed below. Deciphering molecular mechanisms and prioritizing therapeutic targets in cardio-oncology Pau Erola1,2, Benjamin Elsworth1,2, Yi Liu2, Valeriia Haberland2 and Tom R Gaunt1,2,3 1 CRUK Integrative Cancer Epidemiology Programme; 2 MRC Integrative Epidemiology Unit, University of Bristol; 3 The Alan Turing Institute Cancer and cardiovascular disease (CVD) make by far the immense What is EpiGraphDB? contribution to the totality of human disease burden, and although mortality EpiGraphDB is an analytical platform and graph database that aims to is declining the number of those living with the disease shows little address the necessity of innovative and scalable approaches to harness evidence of change (Bhatnagar et al., Heart, 2016).
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy

    Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy

    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
  • 2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development

    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
  • Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Į S a K Y M a S

    Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Į S a K Y M a S

    VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO Į S A K Y M A S DĖL VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO 2006 M. LAPKRIČIO 2 D. ĮSAKYMO NR. 1A-658 „DĖL TARPTAUTINIŲ PREKĖS ŽENKLU NEREGISTRUOTŲ VAISTINIŲ MEDŽIAGŲ PAVADINIMŲ ATITIKMENŲ LIETUVIŲ KALBA SĄRAŠO PATVIRTINIMO“ PAKEITIMO 2013 m. gegužės 2 d. Nr. (1.4)1A-480 Vilnius Atsižvelgdamas į Pasaulio sveikatos organizacijos 2013 m. paskelbtą 69-ąjį Rekomenduojamų tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų (INN) sąrašą, p a k e i č i u Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašą, patvirtintą Valstybinės vaistų kontrolės tarnybos prie Lietuvos Respublikos sveikatos apsaugos ministerijos viršininko 2006 m. lapkričio 2 d. įsakymu Nr. 1A-658 „Dėl Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašo patvirtinimo“ (Žin., 2006, Nr. 119-4557; 2007, Nr. 13-519; 2008, Nr. 24-896; 2010, Nr. 152-7773; 2011, Nr. 56-2700, Nr. 159-7553; 2012, Nr. 53-2664, Nr. 113-5776): 1. Papildau nauja eilute, kurią po eilutės „Actodigin Aktodiginas Actodiginum“ išdėstau taip: „Actoxumab Aktoksumabas Actoxumabum“ 2. Papildau nauja eilute, kurią po eilutės „Alacizumab pegol Alacizumabas pegolas Alacizumabum pegolum“ išdėstau taip: „Aladorian Aladorianas Aladorianum“ 3. Papildau nauja eilute, kurią po eilutės „Alipogene tiparvovec Alipogenas tiparvovekas Alipogenum tiparvovecum“ išdėstau taip: „Alirocumab Alirokumabas Alirocumabum“ 4. Papildau nauja eilute, kurią po eilutės „Antithrombin alfa Antitrombinas alfa Antithrombinum alfa“ išdėstau taip: „Antithrombin gamma Antitrombinas gama Antithrombinum gamma“ 5. Papildau nauja eilute, kurią po eilutės „Astromicin Astromicinas Astromicinum“ išdėstau taip: „Asudemotide Asudemotidas Asudemotidum“ 6. Papildau nauja eilute, kurią po eilutės „Auranofin Auranofinas Auranofinum“ išdėstau taip: „Auriclosene Auriklozenas Auriclosenum“ 7.
  • The Two Tontti Tudiul Lui Hi Ha Unit

    The Two Tontti Tudiul Lui Hi Ha Unit

    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub

    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
  • ADCC Responses and Blocking of EGFR-Mediated Signaling and Cell Growth by Combining the Anti-EGFR Antibodies Imgatuzumab and Cetuximab in NSCLC Cells

    ADCC Responses and Blocking of EGFR-Mediated Signaling and Cell Growth by Combining the Anti-EGFR Antibodies Imgatuzumab and Cetuximab in NSCLC Cells

    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 28), pp: 45432-45446 Research Paper ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells Arjan Kol1, Anton Terwisscha van Scheltinga2, Martin Pool1, Christian Gerdes3, Elisabeth de Vries1 and Steven de Jong1 1Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 3Roche Pharma Research & Early Development, Roche Innovation Center Zürich, Schlieren, Switzerland Correspondence to: Steven de Jong, email: [email protected] Keywords: non-small cell lung cancer, EGFR, imgatuzumab, cetuximab, antibodies Received: October 19, 2016 Accepted: March 30, 2017 Published: April 17, 2017 Copyright: Kol et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Imgatuzumab is a novel glycoengineered anti-epidermal growth factor receptor (EGFR) monoclonal antibody optimized to induce both antibody-dependent cellular cytotoxicity (ADCC) and EGFR signal transduction inhibition. We investigated anti- EGFR monoclonal antibodies imgatuzumab and cetuximab–induced internalization and membranous turnover of EGFR, and whether this affected imgatuzumab–mediated ADCC responses and growth inhibition of non-small cell lung cancer (NSCLC) cells. In a panel of wild-type EGFR expressing human NSCLC cell lines, membranous and total EGFR levels were downregulated more effectively by imgatuzumab when compared with cetuximab.
  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
  • Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine Martin Pool1*, H

    Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine Martin Pool1*, H

    Theranostics 2017, Vol. 7, Issue 7 2111 Ivyspring International Publisher Theranostics 2017; 7(7): 2111-2133. doi: 10.7150/thno.17934 Review Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine Martin Pool1*, H. Rudolf de Boer1*, Marjolijn N. Lub-de Hooge2, 3, Marcel A.T.M. van Vugt1#, Elisabeth G.E. de Vries1# 1. Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 3. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. * Co-first author # Co-senior author Corresponding authors: Elisabeth G.E. de Vries, MD, PhD, Marcel A.T.M. van Vugt, PhD, Department of Medical Oncology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands +31 50 3612934 (EGEdV) / +31 50 3615002 (MATMvV) [email protected] / [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2016.10.15; Accepted: 2017.03.02; Published: 2017.05.27 Abstract Cancer is a growing problem worldwide. The cause of death in cancer patients is often due to treatment-resistant metastatic disease. Many molecularly targeted anticancer drugs have been developed against ‘oncogenic driver’ pathways.
  • CHAPTER 3 Extracellular Domain Shedding Influences Specific Tumor Uptake and Organ Distribution of the EGFR PET Tracer 89Zr-Imgatuzumab

    CHAPTER 3 Extracellular Domain Shedding Influences Specific Tumor Uptake and Organ Distribution of the EGFR PET Tracer 89Zr-Imgatuzumab

    University of Groningen Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy Kol, Klaas Jan-Derk IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2019 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Kol, K. J-D. (2019). Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy. Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 01-10-2021 CHAPTER 3 Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab Martin Pool1 Arjan Kol1 Marjolijn N.